Published in Chem Phys Lipids on December 31, 2002
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol (2006) 1.77
Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol (2004) 1.49
The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A (2006) 1.39
Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol (2006) 1.32
Endocannabinoid mechanisms of pain modulation. AAPS J (2006) 1.28
In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol (2007) 1.20
The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol (2006) 1.16
Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology (2007) 1.11
2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective. J Med Chem (2014) 1.05
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One (2012) 1.05
The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model. Life Sci (2012) 1.04
Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 Å resolution. Protein Sci (2011) 1.03
Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. Br J Pharmacol (2009) 0.96
Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways. Br J Pharmacol (2008) 0.93
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem (2007) 0.92
Mode of action of cannabinoids on nociceptive nerve endings. Exp Brain Res (2009) 0.90
Pharmacological characterisation of place escape/avoidance behaviour in the rat chronic constriction injury model of neuropathic pain. Psychopharmacology (Berl) (2006) 0.87
The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids. Pflugers Arch (2006) 0.78
Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sci (2012) 0.78
Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates. Br J Pharmacol (2007) 0.77
1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor. Bioorg Med Chem (2010) 0.77
The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Med J (2014) 0.76
Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem (2010) 0.76
The effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic rats. Iran J Basic Med Sci (2016) 0.75
Preclinical assessment of novel therapeutics on the cough reflex: cannabinoid agonists as potential antitussives. Lung (2007) 0.75
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Unmasking the tonic-aversive state in neuropathic pain. Nat Neurosci (2009) 2.77
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain (2002) 2.24
Dynorphin A activates bradykinin receptors to maintain neuropathic pain. Nat Neurosci (2006) 2.23
A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther (2004) 2.21
Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem (2004) 2.17
Central modulation of pain. J Clin Invest (2010) 2.12
Multiple actions of systemic artemin in experimental neuropathy. Nat Med (2003) 2.12
AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther (2004) 2.08
Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci (2002) 2.00
Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. Anesthesiology (2007) 1.96
Antinociceptive and nociceptive actions of opioids. J Neurobiol (2004) 1.93
Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol (2004) 1.93
Redistribution of Na(V)1.8 in uninjured axons enables neuropathic pain. J Neurosci (2003) 1.89
Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain (2007) 1.88
Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers (2005) 1.83
Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic pain. Pain (2011) 1.82
Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals (2005) 1.80
The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain (2011) 1.70
Spinal GABA(A) and GABA(B) receptor pharmacology in a rat model of neuropathic pain. Anesthesiology (2002) 1.63
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain (2006) 1.59
Reversal of pancreatitis-induced pain by an orally available, small molecule interleukin-6 receptor antagonist. Pain (2010) 1.58
Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci (2002) 1.58
Peripheral mechanisms of pain and analgesia. Brain Res Rev (2008) 1.55
Parallel synthesis and biological evaluation of different sizes of bicyclo[2,3]-Leu-enkephalin analogues. Biopolymers (2005) 1.54
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
Spinal L-type calcium channel blockade abolishes opioid-induced sensory hypersensitivity and antinociceptive tolerance. Anesth Analg (2005) 1.53
An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain (2005) 1.49
Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain (2005) 1.49
Medullary pain facilitating neurons mediate allodynia in headache-related pain. Ann Neurol (2009) 1.48
CB2 cannabinoid receptor mediation of antinociception. Pain (2006) 1.47
Persistent restoration of sensory function by immediate or delayed systemic artemin after dorsal root injury. Nat Neurosci (2008) 1.47
Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain (2003) 1.46
Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry. Proc Natl Acad Sci U S A (2012) 1.44
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs (2009) 1.42
Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem (2006) 1.40
CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol (2003) 1.39
Impaired nociception and inflammatory pain sensation in mice lacking the prokineticin receptor PKR1: focus on interaction between PKR1 and the capsaicin receptor TRPV1 in pain behavior. J Neurosci (2006) 1.37
Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice. J Clin Invest (2007) 1.37
Lesion of the rostral anterior cingulate cortex eliminates the aversiveness of spontaneous neuropathic pain following partial or complete axotomy. Pain (2011) 1.37
Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain model: role of endogenous opioids. Anesthesiology (2011) 1.35
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis (2009) 1.35
Descending facilitation from the rostral ventromedial medulla maintains visceral pain in rats with experimental pancreatitis. Gastroenterology (2006) 1.34
A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain. Bone (2009) 1.31
The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One (2008) 1.31
Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care (2014) 1.30
Spinal protein kinase M ζ underlies the maintenance mechanism of persistent nociceptive sensitization. J Neurosci (2011) 1.30
Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci (2008) 1.30
Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci (2005) 1.29
Synthesis and investigations of double-pharmacophore ligands for treatment of chronic and neuropathic pain. Bioorg Med Chem (2009) 1.28
Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol (2011) 1.27
Cannabinergic ligands. Chem Phys Lipids (2002) 1.25
Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat (2009) 1.25
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol (2005) 1.24
Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol (2007) 1.24
Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett (2006) 1.23
Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol (2008) 1.22
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav (2007) 1.22
Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors. Brain Res (2009) 1.22
Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem (2007) 1.21
Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists. J Med Chem (2007) 1.21
Pregabalin suppresses spinal neuronal hyperexcitability and visceral hypersensitivity in the absence of peripheral pathophysiology. Anesthesiology (2011) 1.21
Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther (2003) 1.20
Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem (2007) 1.19